Entry Point Capital, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 2,845 shares of CRNX stock, worth $152,947. This represents 0.19% of its overall portfolio holdings.
Number of Shares
2,845Holding current value
$152,947% of portfolio
0.19%Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
244Shares Held
78.2MCall Options Held
268KPut Options Held
197K-
Black Rock Inc. New York, NY6.23MShares$335 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.11MShares$329 Million2.95% of portfolio
-
Wellington Management Group LLP Boston, MA4.62MShares$248 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$243 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.41MShares$237 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.89B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...